CVS Group plc (4C9) AI Stock Analysis

CVS Group plc

(Frankfurt:4C9)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Broad-based revenue and EBITDA growthGrowth across all three divisions indicates broad demand for CVS’s veterinary services rather than reliance on one activity. Combined with maintained EBITDA margins despite inflation, this supports operating resilience and provides a stronger base for reinvestment over the next several quarters.

Negative Factors

Higher leverage reduces financial flexibilityThe material increase in borrowing leaves CVS with less balance-sheet flexibility and a smaller cushion if trading conditions weaken. Higher leverage can also restrict acquisition capacity or require greater cash allocation to debt-related obligations while returns remain modest.

CVS Group plc (4C9) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 908.89M
Dividend Yield: 0.62%
Average Volume (3M): 287
Price to Earnings (P/E): 54.4
Beta (1Y): 0.89
Revenue Growth: 2.40%
EPS Growth: -12.18%
Country: Germany
Employees: 9,000
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Care Facilities

CVS Group plc Business Overview & Revenue Model

Company Description

CVS Group plc, established in 1999 and based in Diss, United Kingdom, is a comprehensive animal care provider with diverse operations. The company's activities are broadly categorized into four segments: Veterinary Practices, Laboratories, Crematoria...

CVS Group plc Earnings Call Summary

Earnings Call Date:Sep 23, 2026(Q4-2026)|% Change Since:2.63%|Next Earnings Date:Mar 03, 2027

Earnings Call SentimentPositive

The call was predominantly positive. CVS delivered revenue, EBITDA, and EPS growth, maintained margins despite inflation, reported a solid start to fiscal 2027, expanded in Australia, returned to U.K. acquisitions, and cited improving veterinary availability, customer metrics, and operating initiatives. The main challenges were softer U.K. consumer conditions, weather-related disruption, routine preventative footfall pressure, ongoing cost inflation, a slight decline in Healthy Pet Club volumes, and prior Animed margin erosion. Highlights significantly outweighed the lowlights.

Positive Updates

Revenue Growth Across All Divisions

Full-year revenue increased by 5.9% to GBP 712.8 million, with all 3 divisions driving growth and improved like-for-like revenue growth versus the prior year.

Negative Updates

Softer Market Conditions in the Final Quarter

The company faced softer market conditions in the final quarter due to continued softer consumer confidence in the U.K. and exceptionally hot spells of weather at the end of May and again at the end of June.

Company Guidance

For FY27, CVS Group said it had a solid start, with August performance back in line with the first half of last year and like-for-like growth of 3% to 4%; it expects to perform in line with market consensus. It expects RDEC income to be similar -- slightly less but similar, actually in the region of GBP 15 million, with GBP 15 million-ish in '27, and expects the provision to reduce further next year. CVS is very confident in its ability to get back to the 4% to 8% range, although it cannot put a date to when it will get back to that 4% level; it expects further growth in labs this year, although last year’s 25% growth is probably more challenging to repeat. The GBP 50 million acquisition allocation will be well spent, and CVS may spend more than GBP 50 million if it has the capital, while 2x remains its stated ceiling for leverage but it may temporarily go above 2x for accretive opportunities; its minimum hurdle rate remains 10% returns.

CVS Group plc Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:4C9 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GB:TSTL	80Outperform	GBP 194.70M	24.28	23.05%	3.51%	10.02%	19.83%
GB:GNS	74Outperform	GBP 1.48B	5.61	44.90%	1.36%	-2.18%	1374.01%
GB:EKF	64Neutral	GBP 102.71M	40.52	3.58%	―	2.26%	-57.04%
GB:EAH	59Neutral	GBP 64.71M	29.26	2.55%	―	9.96%	29.72%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:4C9 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:4C9	CVS Group plc	15.60	1.50	10.63%
GB:EAH	Eco Animal Health	94.50	13.50	16.67%
GB:EKF	EKF Diagnostics Holdings	23.50	-2.50	-9.62%
GB:GNS	Genus plc	2420.00	-13.36	-0.55%
GB:TSTL	Tristel plc	405.00	55.79	15.97%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

CVS Group plc AI Stock Analysis